New review maps risk-guided childhood neuroblastoma care

A new narrative review published Jan. 6 in the World Journal of Pediatric Surgery says childhood neuroblastoma treatment should be driven by risk, not a one-size-fits-all approach. The analysis ties age, tumor biology, imaging, surgery and long-term survivorship into one framework to help clinicians avoid overtreatment in low-risk cases and improve outcomes for high-risk disease.

Why it matters: - Neuroblastoma is the most unpredictable childhood cancer, with some tumors regressing without treatment and others resisting intensive therapy. - Risk-guided care can reduce unnecessary treatment in low-risk disease and focus aggressive therapy where children need it most. - Long-term outcomes depend on more than survival alone, including hearing, fertility, endocrine health, cognition, emotional well-being and secondary cancers.

What happened: - Specialists from the Department of Pediatric Surgery at the Royal Hospital for Children in Glasgow and the Department of Pediatric Surgery at the University of Liverpool published a narrative review on Jan. 6, 2026, in the World Journal of Pediatric Surgery. - The review synthesizes evidence on diagnosis, staging, imaging, pathology, molecular biology, surgery, chemotherapy, immunotherapy, relapse and survivorship in childhood neuroblastoma. - The paper is identified by DOI 10.1136/wjps-2025-001127, with the source available as the published paper.

The details: - Neuroblastoma is the most common solid tumor outside the brain in children younger than 5 and accounts for about 15% of pediatric cancer deaths. - About 70% of patients present with abdominal disease. - Diagnosis commonly combines urine catecholamine testing, MRI, MIBG imaging, bone marrow assessment, biopsy and genetic profiling. - The International Neuroblastoma Risk Group Staging System uses imaging findings and image-defined risk factors to classify localized, metastatic and special metastatic disease before treatment. - MYCN amplification appears in about one-quarter of tumors and in 40% to 50% of high-risk cases, where it signals aggressive behavior. - Five-year survival is above 90% for low- and intermediate-risk disease, but below 60% for high-risk disease. - Treatment can range from observation or surgery alone in selected infants and low-risk patients to chemotherapy, surgery, myeloablative therapy, autologous stem cell rescue, radiotherapy, GD2-targeting monoclonal antibodies and retinoic acid for high-risk disease. - In carefully selected infants monitored without immediate intervention, one prospective study reported 10-year event-free survival of 94.7% and overall survival of 97.4%. - The review says computed tomography may define surgical anatomy better than MRI in some high-risk abdominal tumors. - The survival benefit of more extensive resection remains debated. - Standardized surgical reporting could make future trial comparisons more reliable.

Between the lines: - The review argues that neuroblastoma decisions should be based on age, tumor biology, anatomy and expected response together, not on any single feature. - That approach reflects a broader shift toward personalized pediatric oncology, where the goal is to preserve function while still controlling disease. - The discussion of ALK mutations, telomere biology, GD2-targeting antibodies and chimeric antigen receptor T-cell therapy points to a treatment pipeline that is becoming more targeted.

What's next: - The framework could help surgeons, oncologists, radiologists, pathologists and tumor boards make more consistent decisions about observation, biopsy, surgery and treatment intensification. - Better surgical reporting may improve international trial design and help researchers separate complete resection from incomplete resection. - Future care is likely to focus more on survivorship monitoring and on therapies that control high-risk tumors with less toxicity.

The bottom line: - Neuroblastoma care is moving toward a risk-adapted model that matches treatment intensity to biology, anatomy and long-term harm, not just tumor stage.